Combining EGFR inhibitors with radiation or chemotherapy: Will preclinical studies predict clinical results?

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 3, 2004, Pages 976-983

  Harari, Paul M ^a   Huang, Shyh Min ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Angiogenesis; Apoptosis; Chemotherapy; EGFR; Radiation

Indexed keywords

CELLS; CHEMOTHERAPY; GROWTH KINETICS; SKIN; TOXICITY; TUMORS;

CYTOTOXICITY; EPIDERMAL GROWTH FACTOR RECEPTORS (EGFR); TUMOR CELL GROWTH;

RADIOTHERAPY;

ANTINEOPLASTIC AGENT; CETUXIMAB; CYTOSTATIC AGENT; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; GEMCITABINE; PACLITAXEL; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CELL CYCLE; CELL CYCLE G1 PHASE; CELL INVASION; CELL PROLIFERATION; CHEMOSENSITIVITY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DRUG DESIGN; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PUBLICATION; RADIOSENSITIVITY; RADIOSENSITIZATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR REGRESSION; TUMOR XENOGRAFT;

EID: 0842330212     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.09.097     Document Type: Conference Paper

References (50)

1. Fukuoka M, Yano S, Giaccone G, et al. Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1) [Abstract]. Proc Am Soc Clin Oncol 2002; 21:298a.
2. Kris MG, Natale RB, Herbst RS, et al. A phase II trial of ZD1839 (′Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2) [Abstract]. Proc Am Soc Clin Oncol 2002;21:292a.
3. Cohen E.E.W., Rosen F., Stadler W.M., et al. Phase II Trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 21:2003;1980-1987.
4. 1 arrest in prostatic cancer cell line DU145. Cancer Res. 56:1996;3666-3669.
5. Huang S.-M., Bock J.M., Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59:1999;1935-1940.
6. Prewett M., Rockwell P., Rose C., et al. Altered cell cycle distribution and cyclin-CDK protein expression in A431 epidermoid carcinoma cells treated with doxorubicin and a chimeric monoclonal antibody to epidermal growth factor receptor. Mol Cell Differ. 4:1996;167-186.
7. Zhu X.F., Liu Z.C., Xie B.F., et al. EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. Cancer Lett. 169:2001;27-32.
8. Anderson N.G., Ahmad T., Chan K., et al. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer. 94:2001;774-782.
9. Chan K.C., Knox W.F., Gandhi A., et al. Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation. Br J Surg. 88:2001;412-418.
10. 1 arrest in oral squamous carcinoma cell lines. Oncology. 63:2002;92-98.
11. Huang S.-M., Li J., Armstrong E.A., et al. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res. 62:2002;4300-4306.
12. 1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene. 12:1996;1397-1403.
13. Huang S.-M., Harari P.M. Modulation of radiation response following epidermal growth factor receptor blockade in squamous cell carcinomas inhibition of damage repair, cell cycle kinetics and tumor angiogenesis . Clin Cancer Res. 6:2000;2166-2174.
14. Modjtahedi H., Affleck K., Stubberfield C., et al. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. Int J Oncol. 13:1998;335-342.
15. Wu X., Fan Z., Masui H., et al. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest. 95:1995;1897-1905.
16. Liu B., Fang M., Schmidt M., et al. Induction of apoptosis and activation of the caspase cascade by anti- EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. Br J Cancer. 82:2000;1991-1999.
17. Liu B., Fan Z. The monoclonal antibody 225 activates caspase-8 and induces apoptosis through a tumor necrosis factor receptor family-independent pathway. Oncogene. 20:2001;3726-3734.
18. Ciardiello F., Caputo R., Troiani T., et al. Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. Int J Cancer. 93:2001;172-178.
19. Karashima T., Sweeney P., Slaton J.W., et al. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res. 8:2002;1253-1264.
20. Chan K.C., Knox W.F., Gee J.M., et al. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res. 62:2002;122-128.
21. Ciardiello F., Caputo R., Bianco R., et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 6:2000;2053-2063.
22. Bonner J.A., Raisch K.P., Trummell H.Q., et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol. 18:2000;47S-53S.
23. Bruns C.J., Harbison M.T., Davis D.W., et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res. 6:2000;1936-1948.
24. Prewett M.C., Hooper A.T., Bassi R., et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res. 8:2002;994-1003.
25. Baker C.H., Kedar D., McCarty M.F., et al. Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J Pathol. 161:2002;929-938.
26. Contessa J.N., Reardon D.B., Todd D., et al. The inducible expression of dominant-negative epidermal growth factor receptor-CD533 results in radiosensitization of human mammary carcinoma cells. Clin Cancer Res. 5:1999;405-411.
27. Milas L., Mason K., Hunter N., et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res. 6:2000;701-708.
28. Rao G.S., Murray S., Ethier S.P. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int J Radiat Oncol Biol Phys. 48:2000;1519-1528.
29. Bianco C., Bianco R., Tortora G., et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res. 6:2000;4343-4350.
30. Nasu S., Ang K.K., Fan Z., et al. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys. 51:2001;474-477.
31. Lammering G., Valerie K., Lin P.S., et al. Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor. Clin Cancer Res. 7:2001;682-690.
32. Lammering G., Hewit T.H., Hawkins W.T., et al. Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. J Natl Cancer Inst. 93:2001;921-929.
33. Bianco C., Tortora G., Bianco R., et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res. 8:2002;3250-3258.
34. Williams K.J., Telfer B.A., Stratford I.J., et al. ZD1839 (′Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer. 86:2002;1157-1161.
35. Lawrence T.S., Nyati M.K. Small-molecule tyrosine kinase inhibitors as radiosensitizers. Semin Radiat Oncol. 12:2002;33-36.
36. Magne N., Fischel J.L., Dubreuil A., et al. Sequence-dependent effects of ZD1839 (′Iressa') in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer. 86:2002;819-827.
37. Bandyopadhyay D., Mandal M., Adam L., et al. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem. 273:1998;1568-1573.
38. Sirotnak F.M., Zakowski M.F., Miller V.A., et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res. 6:2000;4885-4892.
39. Ciardiello F., Bianco R., Damiano V., et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res. 5:1999;909-916.
40. Raben D., Helfrich B.A., Chan D., et al. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol. 29:2002;37-46.
41. Perrotte P., Matsumoto T., Inoue K., et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res. 5:1999;257-264.
42. Inoue K., Slaton J.W., Perrotte P., et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res. 6:2000;4874-4884.
43. Kedar D., Baker C.H., Killion J.J., et al. Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice. Clin Cancer Res. 8:2002;3592-3600.
44. Gille J., Swerlick R.A., Caughman S.W. Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J. 16:1997;750-759.
45. O-Charoenrat P., Rhys-Evans P., Modjtahedi H., et al. Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. Clin Exp Metastasis. 18:2000;155-161.
46. Ciardiello F., Caputo R., Bianco R., et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res. 7:2001;1459-1465.
47. Hirata A., Ogawa S., Kometani T., et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res. 62:2002;2554-2560.
48. Giaccone G, Johnson D, Scagliotti GV, et al. Results of a multivariate analysis of prognostic factors of overall survival of patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib (ZD1839) in combination with platinum-based chemotherapy (CT) in two large phase III trials (INTACT 1 and 2) [Abstract]. Proc Am Soc Clin Oncol 2003;22:627.
49. Giaccone G., Johnson D.H., Manegold C., et al. A phase III clinical trial of ZD1839 (′Iressa') in combination with gemcitabine and cisplatin in chemotherapy naive patients with advanced non-small-cell lung cancer (INTACT 1). Ann Oncol. 13:(Suppl. 5):2002;2-3.
50. Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 19:2000;6550-6565.